Cook Nancy R, Albert Christine M, Gaziano J Michael, Zaharris Elaine, MacFadyen Jean, Danielson Eleanor, Buring Julie E, Manson JoAnn E
Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Ave E, Boston, MA 02215, USA.
Arch Intern Med. 2007;167(15):1610-8. doi: 10.1001/archinte.167.15.1610.
Randomized trials have largely failed to support an effect of antioxidant vitamins on the risk of cardiovascular disease (CVD). Few trials have examined interactions among antioxidants, and, to our knowledge, no previous trial has examined the individual effect of ascorbic acid (vitamin C) on CVD.
The Women's Antioxidant Cardiovascular Study tested the effects of ascorbic acid (500 mg/d), vitamin E (600 IU every other day), and beta carotene (50 mg every other day) on the combined outcome of myocardial infarction, stroke, coronary revascularization, or CVD death among 8171 female health professionals at increased risk in a 2 x 2 x 2 factorial design. Participants were 40 years or older with a history of CVD or 3 or more CVD risk factors and were followed up for a mean duration of 9.4 years, from 1995-1996 to 2005.
A total of 1450 women experienced 1 or more CVD outcomes. There was no overall effect of ascorbic acid (relative risk [RR], 1.02; 95% CI, 0.92-1.13 [P = .71]), vitamin E (RR, 0.94; 95% CI, 0.85-1.04 [P = .23]), or beta carotene (RR, 1.02; 95% CI, 0.92-1.13 [P = .71]) on the primary combined end point or on the individual secondary outcomes of myocardial infarction, stroke, coronary revascularization, or CVD death. A marginally significant reduction in the primary outcome with active vitamin E was observed among the prespecified subgroup of women with prior CVD (RR, 0.89; 95% CI, 0.79-1.00 [P = .04]; P value for interaction, .07). There were no significant interactions between agents for the primary end point, but those randomized to both active ascorbic acid and vitamin E experienced fewer strokes (P value for interaction, .03).
There were no overall effects of ascorbic acid, vitamin E, or beta carotene on cardiovascular events among women at high risk for CVD.
随机试验在很大程度上未能证实抗氧化剂维生素对心血管疾病(CVD)风险有影响。很少有试验研究抗氧化剂之间的相互作用,据我们所知,此前没有试验研究过抗坏血酸(维生素C)对CVD的单独作用。
女性抗氧化剂心血管研究采用2×2×2析因设计,测试了抗坏血酸(500毫克/天)、维生素E(隔日600国际单位)和β-胡萝卜素(隔日50毫克)对8171名CVD风险增加的女性健康专业人员心肌梗死、中风、冠状动脉血运重建或CVD死亡这一联合结局的影响。参与者年龄在40岁及以上,有CVD病史或3种及以上CVD风险因素,随访时间平均为9.4年,从1995 - 1996年至2005年。
共有1450名女性经历了1种或更多CVD结局。抗坏血酸(相对风险[RR],1.02;95%置信区间,0.92 - 1.13 [P = 0.71])、维生素E(RR,0.94;95%置信区间,0.85 - 1.04 [P = 0.23])或β-胡萝卜素(RR,1.02;95%置信区间,0.92 - 1.13 [P = 0.71])对主要联合终点或心肌梗死、中风、冠状动脉血运重建或CVD死亡的各个次要结局均无总体影响。在预先指定的有既往CVD的女性亚组中,观察到活性维生素E使主要结局有边缘性显著降低(RR,0.89;95%置信区间,0.79 - 1.00 [P = 0.04];交互作用P值,0.07)。主要终点方面各药物之间无显著交互作用,但随机分配到活性抗坏血酸和维生素E组的女性中风较少(交互作用P值,0.03)。
抗坏血酸、维生素E或β-胡萝卜素对CVD高危女性心血管事件无总体影响。